Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Legend Biotech ( (LEGN) ) is now available.
On November 3, 2025, Legend Biotech announced its participation in the 67th American Society of Hematology Annual Meeting, where it will present research on CARVYKTI® and a novel therapy, Lucar-G39D. These presentations highlight the company’s ongoing innovation in cell therapy and its efforts to expand treatment options for multiple myeloma and B-cell non-Hodgkin lymphoma, potentially impacting clinical practices and patient outcomes.
The most recent analyst rating on (LEGN) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page.
Spark’s Take on LEGN Stock
According to Spark, TipRanks’ AI Analyst, LEGN is a Neutral.
Legend Biotech’s overall stock score is driven by its financial performance challenges, particularly in profitability and cash flow, which weigh heavily on the score. Despite these issues, the positive sentiment from the recent earnings call, highlighting significant sales growth and strategic advancements, provides a counterbalance. Technical indicators suggest a bearish trend, and valuation metrics are unattractive due to negative earnings. The absence of corporate events does not impact the score.
To see Spark’s full report on LEGN stock, click here.
More about Legend Biotech
Legend Biotech Corporation is a global leader in cell therapy, focusing on innovative treatments for cancer. Their primary product, CARVYKTI®, is a BCMA-targeted CAR-T cell therapy approved for multiple myeloma and is commercially available in 14 countries.
Average Trading Volume: 1,202,575
Technical Sentiment Signal: Sell
Current Market Cap: $5.98B
For a thorough assessment of LEGN stock, go to TipRanks’ Stock Analysis page.